DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
Clinical Trials for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00004767 | Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders | Completed | Johns Hopkins University | Phase 2 | OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders. |
| NCT00004767 | Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders | Completed | National Center for Research Resources (NCRR) | Phase 2 | OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders. |
| NCT00074165 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | Terminated | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma. |
| NCT00074165 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | Terminated | OHSU Knight Cancer Institute | Phase 2 | RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma. |
| NCT00075387 | Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors | Recruiting | National Cancer Institute (NCI) | Phase 2 | This randomized phase II trial studies how well giving combination chemotherapy with or without sodium thiosulfate works in preventing low platelet count while treating patients with malignant brain tumors. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sodium thiosulfate may prevent low platelet counts in patients receiving chemotherapy. It is not yet known whether combination chemotherapy is more effective with or without sodium thiosulfate in preventing low platelet count during treatment for brain tumors. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Condition Name
| Condition Name for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Intervention | Trials |
| Colonoscopy | 9 |
| Healthy | 5 |
| Anterior Uveitis | 3 |
| Early Childhood Caries | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
Condition MeSH
| Condition MeSH for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Intervention | Trials |
| Renal Insufficiency, Chronic | 4 |
| Iridocyclitis | 4 |
| Kidney Diseases | 4 |
| Uveitis, Anterior | 4 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
Clinical Trial Locations for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Clinical Trial Progress for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Clinical Trial Phase
Clinical Trial Status
| Clinical Trial Status for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Clinical Trial Phase | Trials |
| Completed | 55 |
| Recruiting | 22 |
| Not yet recruiting | 11 |
| [disabled in preview] | 15 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
Clinical Trial Sponsors for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Sponsor Name
| Sponsor Name for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Sponsor | Trials |
| National Cancer Institute (NCI) | 5 |
| OHSU Knight Cancer Institute | 4 |
| Erydel | 4 |
| [disabled in preview] | 6 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
Sponsor Type
